M2613
M2613 is a nonsteroidal estrogen derived from triphenylbromoethylene which was studied in the treatment of breast cancer in women in the 1940s but was never marketed.[1][2]
 | |
| Clinical data | |
|---|---|
| Other names | M-2613; Methoxyethoxy-triphenylbromoethylene |
| Drug class | Nonsteroidal estrogen |
| Identifiers | |
| |
| CAS Number | |
| Chemical and physical data | |
| Formula | C23H21BrO2 |
| Molar mass | 409.323 g·mol−1 |
See also
References
- Walpole AL, Paterson E (October 1949). "Synthetic oestrogens in mammary cancer". Lancet. 2 (6583): 783–6. doi:10.1016/s0140-6736(49)91370-7. PMID 15391512.
- Jordan VC (February 2015). "The new biology of estrogen-induced apoptosis applied to treat and prevent breast cancer". Endocr. Relat. Cancer. 22 (1): R1–31. doi:10.1530/ERC-14-0448. PMC 4494663. PMID 25339261.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.